Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
| Revenue (TTM) | $63.62B |
| Gross Profit (TTM) | $47.65B |
| EBITDA | $24.94B |
| Operating Margin | 33.40% |
| Return on Equity | 4.47% |
| Return on Assets | 5.59% |
| Revenue/Share (TTM) | $11.17 |
| Book Value | $15.61 |
| Price-to-Book | 1.88 |
| Price-to-Sales (TTM) | 2.63 |
| EV/Revenue | 3.394 |
| EV/EBITDA | 16.03 |
| Quarterly Earnings Growth (YoY) | -9.70% |
| Quarterly Revenue Growth (YoY) | -0.40% |
| Shares Outstanding | $5.70B |
| Float | $5.69B |
| % Insiders | 0.10% |
| % Institutions | 68.95% |
Volatility is currently expanding
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer acquired a promising GLP-1 drug last year through its purchase of Metsera. It plans to eventually launch both weekly and monthly versions of the treatment.
A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.
Six S&P 500 'safer' high-yield dividend stocks—Regions Financial, Ford, AT&T, Pfizer, Verizon, VICI Properties—currently offer attractive buy signals based on free cash flow yields. Analyst projections for the top ten S&P 500 dividend dogs indicate potential net gains of 14.54% to 40.07% by November 2027, with an average estimated gain of 27.42%. Dividend dog strategy favors stocks where annual dividends from $1,000 invested exceed single-share prices and free cash flow yields surpass dividend yields.
The Fund returned 3.18% compared to a 2.61% return for the Russell 1000 Value Index. Key contributors include Microsoft, Salesforce and Thermo Fisher Scientific. Key detractors include Aon, Carrier Global and Builders FirstSource.
Drugs, software, cereal, and electricity keep selling when the economy stalls. Five dividend payers pass a coverage test, but one carries a payout stretched thin and another faces a regulatory hearing that could change its income story.
Amgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases. Pfizer maintains a massive global reach and offers a more conservative balance sheet with a lower valuation profile.
When a heavily indebted company has to refinance at higher rates, every extra dollar of interest comes out of the same cash pool that funds the dividend. Bondholders have a legal claim on that cash.
Pfizer remains a Buy as its robust pipeline and strategic acquisitions drive portfolio adaptation ahead of the LOE cliff. PFE delivered a double-beat Q3, raised 2026 guidance, and posted strong non-COVID product growth, offsetting COVID-19 revenue declines. Major acquisitions combined with aggressive cost savings position PFE for strong post-LOE performance and diversification.
Pfizer delivered Q3 2026 revenue of $16.58B and adjusted EPS of $0.87, beating consensus and raising full-year guidance for the second time. PFE's non-COVID portfolio grew 7% operationally, with launched and acquired products up 32%, offsetting steep COVID-related declines. Management now guides 2026 revenue to $62–$64B and adjusted EPS to $2.95–$3.05, with cost savings and a 5.73% dividend yield well covered by FCF.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PFE and any ticker you trade — then tracks every position and per-strategy win rate.
